Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last941 to 960 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: Death From Any Cause in the Glycemia Trial. | 391 of 5,128 327 of 5,123 | 1.2 points 0.3 to 2.2 | 10,251 | NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) |
| Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial. | 503 of 5,128 543 of 5,123 | -0.8 points -2.0 to 0.4 | 10,251 | NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) |
| Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: serious adverse events | 137 of 5,128 107 of 5,123 | 0.6 points -0.0 to 1.2 | 10,251 | NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) |
| Vitamins vs Placebo: deaths from any cause | 1 of 5,087 1 of 5,065 | -0.0 points -0.1 to 0.1 | 10,152 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: serious adverse events | 108 of 5,087 173 of 5,065 | -1.3 points -1.9 to -0.7 | 10,152 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Serious TEAE | 55 of 5,064 51 of 5,072 | 0.1 points -0.3 to 0.5 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Solicited Local and Systemic Reactions | 75 of 5,064 85 of 5,072 | -0.2 points -0.7 to 0.3 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Unsolicited TEAEs | 13 of 5,064 25 of 5,072 | -0.2 points -0.5 to 0.0 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Related Unsolicited Reactions | 4 of 5,064 6 of 5,072 | -0.0 points -0.2 to 0.1 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | 54 of 5,064 41 of 5,072 | 0.3 points -0.1 to 0.6 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Solicited Local and Systemic Reactions | 2,776 of 5,064 1,723 of 5,072 | 20.8 points 18.9 to 22.7 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Immediate Complaint | 441 of 5,064 377 of 5,072 | 1.3 points 0.2 to 2.3 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Related Solicited Reactions | 56 of 5,064 62 of 5,072 | -0.1 points -0.5 to 0.3 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | 661 of 5,064 639 of 5,072 | 0.5 points -0.8 to 1.8 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One AE Leading to Withdrawal | 0 of 5,064 5 of 5,072 | -0.1 points -0.2 to -0.0 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: Number of Participants With an Occurrence of Death | 1 of 5,064 2 of 5,072 | -0.0 points -0.1 to 0.1 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: deaths from any cause | 1 of 5,064 2 of 5,072 | -0.0 points -0.1 to 0.1 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Quadrivalent VLP Vaccine vs Placebo: serious adverse events | 55 of 5,064 51 of 5,072 | 0.1 points -0.3 to 0.5 | 10,136 | NCT03301051 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults |
| Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Return of Spontaneous Circulation (ROSC) | 544 of 1,486 3,118 of 8,641 | 0.5 points -2.1 to 3.2 | 10,127 | NCT02142387 Effects of a New Dispatcher-Assisted Basic Life Support Training Program |
| Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants Surviving to Hospital Discharge | 85 of 1,486 551 of 8,641 | -0.7 points -1.9 to 0.7 | 10,127 | NCT02142387 Effects of a New Dispatcher-Assisted Basic Life Support Training Program |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=48
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00000620-30270839",
"title": "Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: Death From Any Cause in the Glycemia Trial.",
"summary": "391 of 5128 against 327 of 5123; risk difference 1.2 points, 95% interval 0.3 to 2.2; NCT00000620, Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
"record": "/library/comparisons/NCT00000620-30270839",
"nct_id": "NCT00000620",
"kind": "outcome",
"participants": 10251,
"risk_difference": {
"value": 0.012418262687954332,
"lower": 0.002534915276932413,
"upper": 0.022325055495918684
},
"group_1": "391 of 5,128",
"group_2": "327 of 5,123",
"difference": "1.2 points",
"interval": "0.3 to 2.2",
"trial_title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)"
},
{
"id": "NCT00000620-3875dea1",
"title": "Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.",
"summary": "503 of 5128 against 543 of 5123; risk difference -0.8 points, 95% interval -2.0 to 0.4; NCT00000620, Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
"record": "/library/comparisons/NCT00000620-3875dea1",
"nct_id": "NCT00000620",
"kind": "outcome",
"participants": 10251,
"risk_difference": {
"value": -0.007903658914266004,
"lower": -0.019636397863784117,
"upper": 0.003822394235238504
},
"group_1": "503 of 5,128",
"group_2": "543 of 5,123",
"difference": "-0.8 points",
"interval": "-2.0 to 0.4",
"trial_title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=49",
"request_id": "dSpC0hJgTaTKf15P"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant